Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514485 | 0.91 | BRD4 (0.46) | TRPV1BRD4NPC1TP53MAPT | |
| SCHEMBL4535111 | 0.86 | TRPV1 (0.48) | TRPV1NPC1TP53MAPTMAPK1 | |
| SCHEMBL4529131 | 0.85 | TRPV1 (0.47) | TRPV1NPC1RAB9ASMN1; SMN2ALOX5AP | |
| SCHEMBL4533261 | 0.84 | TRPV1 (0.50) | TRPV1NPC1TP53MAPK1RAB9A | |
| SCHEMBL2240908 | 0.84 | TRPV1 (0.58) | TRPV1BRD4ALOX5APFEN1SCN9A | |
| SCHEMBL4528304 | 0.84 | BRD4 (0.50) | TRPV1BRD4NPC1TP53MAPT | |
| SCHEMBL4528407 | 0.84 | TRPV1 (0.47) | TRPV1BRD4ALOX5APFEN1 | |
| SCHEMBL4533880 | 0.82 | TRPV1 (0.51) | TRPV1NPC1TP53MAPK1RAB9A | |
| SCHEMBL4527777 | 0.82 | TRPV1 (0.56) | TRPV1NPC1TP53MAPK1RAB9A | |
| SCHEMBL4524571 | 0.82 | TRPV1 (0.62) | TRPV1NPC1TP53MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| WO-2008076752-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | TRPV1 1/4885BRD4 352/4885NPC1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.